You can Subscribe to our RSS FEED: which delivers brain tumor news and additions to the website via RSS.
Click HERE for details on RSS.
Displaying items 3676 to 3700 of about 5880
Next 25
03/10/2008
New Drug for Brain Cancer Too Dangerous for Pediatric Patients
03/09/2008
Upcoming Brain Tumor Conferences
Gene Therapy `Trains` Immune System to Destroy Brain Cancer Cells and Reverse Behavioral Deficits
03/07/2008
A Viral Attack against Brain Tumors A rabies-related virus seeks out and destroys tumors in the brain.
Sun Trust Bank - fundraiser for the Musella Foundation
03/06/2008
Run and Motorcycle Ride Honoring Dr. Marnie Rose Celebrates Six Year Anniversary
02/27/2008
“A Night of Hope & Dreams” Gala to Support Local Pediatric Brain Tumor Foundation
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Tug McGraw Foundation Announces Team McGraw Participation In Country Music 1/2 Marathon
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Children`s Brain Treatment Boosted
02/25/2008
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
Natural history and management of brainstem gliomas in adults : A retrospective Italian study.
02/23/2008
New MRI Opens New Doors
Tumor-killing virus selectively targets diseased brain cells
UCLA 8th Annual Brain Tumor Conference
02/17/2008
Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor.
02/15/2008
Anti-cancer drug damages brain vessels
New Treatment Found for Recurring Brain Tumors
TransMolecular`s anticancer drug receives orphan drug designation
YM BioSciences US unit enrolls first patient for phase II trial of nimotuzumab
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.